TNF and rheumatoid arthritis: First, Pers et al. evaluated periodontal condition in 20 French patients with RA who had received infliximab (IFX, a chimeric mouse/human anti-TNF-α monoclonal antibody) every 6 weeks for more than 22 months and 20 race-, age-, gender-, and smoking status-balanced patients with RA who had not received IFX medication [80].